Skip to main content
. 2020 Oct 30;21:900. doi: 10.1186/s13063-020-04760-x

Table 2.

Table of participant randomisation groups and laboratory analysis of foreskins

Stage 1: Oral PrEP taken by men Foreskin tissue divided in the lab Stage 2: In vitro dosing of tissue in the laboratory
Randomised arm N Oral PrEP analysis group Oral drug Number of PrEP doses Interval between last oral PrEP and VMMC (h) In vitro analysis group In vitro drug Interval between ex vivo HIV exposure and in vitro dose (h)
1 16 X No PrEP X-0 No PrEP
X-TDF FTC-TDF 18
X-TAF FTC-TAF 18
2 16 A FTC-TDF 1 5 A-5-0 No PrEP
A-5-TDF FTC-TDF 18
3 16 FTC-TDF 1 21 A-21-0 No PrEP
A-21-TDF FTC-TDF 18
4 16 B FTC-TDF 2 5 B-5-0 No PrEP
B-5-TDF FTC-TDF 18
5 16 FTC-TDF 2 21 B-21-0 No PrEP
B-21-TDF FTC-TDF 18
6 16 C FTC-TAF 1 5 C-5-0 No PrEP
C-5-TAF FTC-TAF 18
7 16 FTC-TAF 1 21 C-21-0 No PrEP
C-21-TAF FTC-TAF 18
8 16 D FTC-TAF 2 5 D-5-0 No PrEP
D-5-TAF FTC-TAF 18
9 16 FTC-TAF 2 21 D-21-0 No PrEP
D-21-TAF FTC-TAF 18

The in vitro analysis groups comprise three components: a letter indicating the stage 1 group, a number (5 or 21) indicating the interval between the last oral PrEP dose and circumcision and an item indicating in vitro dosing (where 0 = no dose). The exceptions are the group of men who did not receive oral PrEP (group X): these groups do not include the middle component